A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

Tirzepatide has been approved by the U.S. FDA as Mounjaro for adults with type 2 diabetes to improve glycemic control, and as Zepbound for adults with obesity, or some adults who are overweight ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period ...

This study highlights the rapid and significant uptake of tirzepatide across populations with and without type 2 diabetes, within 18 months of its approval. Among adults with type 2 diabetes ...

Study: Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials. Image Credit: Dragana Gordic / Shutterstock In a ...

Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide ...

The approval of tirzepatide for type 2 diabetes and obesity management has shifted first-line therapy, impacting research, healthcare costs, and policy. The study underscores the dynamic nature of ...

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial ...

Those with CKD receiving tirzepatide had larger urine albumin-to-creatinine ratio reductions. Perspective from M. Luiza Caramori, MD, MSc, PhD Adults with type 2 diabetes receiving tirzepatide had ...

While this study offered encouraging news for adults without diabetes, ongoing research will determine if tirzepatide offers similar long-term benefits for other groups. Investigations continue ...

tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85 th Scientific Sessions taking place June 20-23 in ...